Ranking: Massachusetts #1 in biotech IPOs

(The Boston Globe, November 06, 2013)

Karyopharm, an only four-year-old Massachusetts biotech company raised $109 million in an initial public offering. The company is working on discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases. The principle of this class of drugs is to aid the bodys natural tumor-supressing mechanisms. The company’s lead drug candidate, called Selinexor, is in early-stage clinical trials. Karyopharm became the ninth Massachusetts biotechnology company to complete an IPO this year, placing the state’s sector first in the nation in minting public companies.